Brief: Cytodyn Signs Letter Of Intent For The Joint Development And Licensing Of Leronlimab In China With Longen China Group
12/02/2020 14:16
Feb 12 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN SIGNS LETTER OF INTENT FOR THE JOINT DEVELOPMENT
AND
LICENSING OF LERONLIMAB IN CHINA WITH LONGEN CHINA GROUP
* CYTODYN INC - CO, LONGEN WILL BEGIN EXPLORING
OPPORTUNITIES FOR
LERONLIMAB FOR TREATMENT OF 2019 NOVEL CORONAVIRUS AND CANCER
Source text for Eikon: ID:nGNXnSbYr
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer